Goldman Small Cap Research Issues Research Report on BioCorRx Inc.

BALTIMORE, July 24, 2014 /PRNewswire/ -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, announced today that it has released a new research report on BioCorRx, Inc. (OTCQB – BICX). The healthcare solutions company is on the leading edge of substance abuse addiction treatment. BioCorRx developed the highly effective Start Fresh Program™ which is sold to and used by addiction clinics across the U.S.

The alcohol and substance addiction treatment market is huge, with $23 billion spent annually. According to the Centers for Disease Control and Prevention, 38 million Americans are considered heavy drinkers, consuming more than three drinks per day. The impact of this disease on our economy is staggering. The CDC estimates that alcoholism costs the U.S. economy $220 billion each year.

The first component of BioCorRx's Start Fresh Program™ program consists of an outpatient implant procedure performed by a physician that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component is a one-on-one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.

"One of the primary issues affecting addiction treatment efficacy is patient non-compliance. In contrast, patients have been engaged in the Company's innovative two-pronged treatment approach since its introduction to the public. Therefore, we believe that BioCorRx may have developed the holy grail of alcohol treatment. As the number of success stories grows, BioCorRx's Start Fresh Program could become the go-to addiction treatment program of choice."

"Going forward, we believe that the Company's business model should result in major operating profits beginning next year as meaningful market penetration into a number of clinics occurs. Revenue is generated via program sales on a per-patient basis and the low-overhead BioCorRx model benefits from clinics' advertising and marketing campaigns."

This press release contains excerpts of our most recently published sponsored research report on BioCorRx Inc. Goldman Small Cap Research has been compensated by the Company in the amount of $6400 for a research subscription service. To view the sponsored research report, disclosures and disclaimers, or to download the report in its entirety, please visit www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters.  Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About BioCorRx Inc.:

BioCorRx Inc. is a healthcare solutions company on the leading edge of substance abuse addiction treatment. BioCorRx developed the highly effective Start Fresh Program™ which is sold to and used by addiction clinics across the U.S. The first component of the program consists of an outpatient implant procedure performed by a physician that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component is a one-on-one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions.

For more information visit BioCorRx, Inc.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
[email protected]

SOURCE Goldman Small Cap Research